This year has been a pivotal one for Beckman Coulter, with an expansion of its customer base across a range of laboratory sizes. Here, Leanne Annereau talks about recent successes and future prospects.
When Beckman Coulter was acquired by the Danaher Corporation two years ago it became part of a global operation that puts great emphasis on integrity and compliance in its business commitment to customers. Its brands are already leaders in their field, and, once part of the Danaher portfolio, are given added impetus to drive forward their leading-edge technologies and innovative solutions.
Beckman Coulter is recognised worldwide for its automated testing platforms serving the core laboratory. “We have always understood that for innovation to be successful over the long-term, the company must provide value-driven solutions that improve overall workflow efficiency, whatever the size of the laboratory,” explained Leanne Annereau, marketing manager, Northern Region, in an interview with Pathology in Practice.
The parent company’s ability to move fast in acquiring other companies is another advantage. The recent addition of Iris Diagnostics, an industry leader in automated urinalysis, is of particular benefit to Beckman Coulter‘s UK customers. “The acquisition completes a gap in our portfolio and further advances our goal of serving the needs of the core laboratory,” she added.
Urine microscopy in the UK focuses on culture candidate screening, unlike the rest of Europe. Automation for this screening step is becoming more widespread, with the high-throughput Iris iQ200 the fastest system on the market. It runs more than 100 samples per hour and, with its distinctive technologies, is best suited to UK requirements.”
Log in or register FREE to read the rest
This story is Premium Content and is only available to registered users. Please log in at the top of the page to view the full text.
If you don't already have an account, please register with us completely free of charge.